Effects of pupil-dilating drug on myopia progression and intraocular pressure elevation

Submission date 19/01/2016	Recruitment status No longer recruiting	Prospectively registered		
		☐ Protocol		
Registration date 31/05/2016	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
30/11/2020	Eve Diseases			

Plain English summary of protocol

Background and study aims

Short-sightedness, or myopia, is a common eye condition resulting in distant objects appearing blurred to the sufferer. The condition usually starts from around puberty, but can develop in younger children. The condition gradually gets worse over time. It is caused by the eye stretching and becoming slightly longer than it should. This means that light does not focus on the retina (light-sensitive tissue) of the eye but just in front of it, causing far away objects to look blurred. Myopia is associated with an increase in pressure within the eye (intraocular pressure) over a long period of time. Some studies have shown that the drug atropine slows down the progression of myopia. This study looks at the effects of topical atropine (atropine given as eye drops) on the intraocular pressure of the eye and myopia progression in children and aims to find out the smallest amount of drug that needed (lowest concentration) to get results.

Who can participate?

Short-sighted children aged between 6 and 12 and living in Northern Taiwan.

What does the study involve?

Children are assigned to one of three groups. If the parents state a preference for the child not to be treated with medication, they are assigned to the control group and given glasses to correct their vision if required. If the parents state a preference for their child to be treated with medication, they are randomly allocated to one of two groups. Children in group 2 are given eye drops containing 0.125% atropine in addition to corrective glasses if required. Children in group 3 are given eye drops containing 0.25% atropine in addition to corrective glasses if required. Myopia progression and intraocular pressure is measured at the start of the study and then every 3 months for the next 12 months for all participants.

What are the possible benefits and risks of participating?

In general, there is almost no risk for taking part in this study because atropine use in Taiwan is routine and general practice for myopic children. The only risk, if any, is that those who did not use atropine (control group) will run a rapid myopic progression speed and have a greater chance of high myopia and associated complications during their late adult life.

Where is the study run from? Chang Gung Memorial Hospital (Taiwan)

When is the study starting and how long is it expected to run for? March 2009 to March 2011

Who is funding the study? Chang Gung Medical Research Foundation

Who is the main contact? Dr Chi-Chin Sun

Contact information

Type(s)

Scientific

Contact name

Dr Chi-Chin Sun

Contact details

6F, Department of Ophthalmology Chang Gung Memorial Hospital 222, MaiJing Rd An Leh District Keelung Taiwan 204

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title

Effects of topical atropine on intraocular pressure and myopia progression

Study objectives

Topical atropine has been used for a long time to control myopia progression. However, the minimal effective concentration has not been established. Moreover, its effect on intraocular pressure is still in debate. Therefore, we conducted this prospective study.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Institutional Review Board at Chang Gung Memorial Hospital, Taiwan, 30/01/2009, ref: 97-1988A3

Study design

Single site prospective, interventional longitudinal and non-randomized study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Myopia in children

Interventions

This is an interventional study that enrolled children with myopia. If the parents state a preference for their child to not receive any medications, they are assigned to the control group with spectacles correction if needed.

If their parents state a preference for their child to be treated with medications, the child is randomly assigned to one of two groups:

- 1. Child is treated with 0.125% atropine in addition to spectacle correction
- 2. Child is treated with 0.25% atropine in addition to spectacle correction All children are followed up for the next 12 months.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Atropine

Primary outcome(s)

Myopia and its progression: with autorefractometer and manifest refraction by experienced technician. Assessed at baseline and then every 3 months for next 12 months.

Key secondary outcome(s))

IOP measurement: with pneumatic tonometer by experienced technician. Assessed at baseline and then every 3 months for next 12 months.

Completion date

01/03/2011

Eligibility

Key inclusion criteria

- 1. Children in Northern Taiwan aged between 6 to 12 years.
- 2. Patients with a refractive error less than -3.0 diopters (D)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

6 years

Upper age limit

12 years

Sex

Αll

Total final enrolment

56

Key exclusion criteria

- 1. Congenital eye disorder
- 2. Any disease influence the cornea, lens or retina
- 3. Best correct visual acuity<20/25 using the Snellen chart
- 4. Primary intraocular pressure above 21mmHg
- 5. Atropine application within 6 months before enrollment
- 6. Patients who could understand the details of this study or could not adhere to the follow up schedule

Date of first enrolment

01/05/2009

Date of final enrolment

31/12/2010

Locations

Countries of recruitment

Taiwan

Study participating centre Chang Gung Memorial Hospital

Keelung Taiwan 204

Sponsor information

Organisation

Chang Gung Memorial Hospital

ROR

https://ror.org/02verss31

Funder(s)

Funder type

Research organisation

Funder Name

Chang Gung Medical Research Foundation

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	19/07/2016	30/11/2020	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes